Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Paysign and EvoShare Announce Partnership
Paysign's Reward Program Provides More Cash Back
Offers with EvoShare
Henderson, Nev. - December 15, 2022 - (Business Wire) - Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing, and EvoShare, a microsavings-oriented fintech startup based in Berkeley, CA, today announced a new partnership and integrated experience to bring more savings and reward opportunities to Paysign clients and cardholders.
This partnership will allow Paysign to provide additional cash back rewards through their Paysign Pays Cashback Rewards program. EvoShare’s proprietary system returns a percentage of every dollar spent at more than 10,000 partnered local restaurants and online stores and over 850,000 hotels worldwide to the participant’s Paysign Pays Cashback Rewards preferred account.
Paysign Pays Cashback Rewards users can also take advantage of new features and earn more cash back at newly added retailers, hotels, theme parks, and car rentals, as well as offers from thousands of local restaurants. Another additional feature is the browser extension that can be downloaded to instantly notify the user of cash back offers while they browse online.
Paysign’s President and COO, Matt Lanford, stated, “We are pleased to develop this partnership with EvoShare and look forward to the improvements our alignment will bring to Paysign Pays Cashback Rewards users. We are excited for future phases of our product development with EvoShare, as well as continuing to bring added value to our customers and clientele."
Eugeny Prudchyenko, EvoShare CEO, said, “We’re confident the partnership between EvoShare and Paysign will make earning cash back easier for Paysign cardholders.”
Paysign and EvoShare’s integrated rewards program is now available free for all Paysign cardholders, as the solution opens up the door for all Paysign Pays users to start utilizing the exciting new features and benefits. Users shop and dine as usual at participating merchants and the cash back earnings are automatically deposited onto their Paysign debit card.
janey, i'm with you---plenty of if's here----backed by babyf news somewhat----but fobif is different imho...far more spec-ish----pays seems more sensible in comparison to both. i own babyf and pays---discarded my fobif
i decided to more heavily weight pays- but i can't let go of my babyf shares..............they're now in china with some tick-tock. The chinese respect israeli products, i'm speculating. We'll see.
still holding here- grinding and gritting my teeth--------------will be needing braces soon, i suspect. (hee hee hee).
yeah, our tough luck...
tough luck for all of us
ON MY STOCK SCREEN I HAVE HAD THE SAME 50+ UNDER THE RADAR STOCKS WITH POTENTIAL: pays IS MY TOP PICK. sorry about the damn caps- my keyboard sticks and i'm too lazy to fix it,.....of those 50+ picks, pays has held up best. This has been a DEPLORABLE year under biden. lol---------------------Looking to add some more pats soon under 3.00.
dripping up is simply grand--accumulation continues...
PaySign: Steady As She Goes
Nov. 20, 2022 7:39 AM ETPaySign, Inc. (PAYS)
Gary Bourgeault profile picture
Gary Bourgeault
12.68K Followers
Summary
The positives and negatives of being heavily reliant on one market.
Why PAYS should maintain a modest, positive growth trajectory in the quarters ahead.
The recent U.S. District Court's injunction will play a significant role in company growth going forward.
Close-up of IV drip bag
Portra/E+ via Getty Images
PaySign, Inc. (NASDAQ:PAYS) reported a good quarter recently, as its core plasma business continues to grow based upon more wins, increased demand and a recent injunction from a U.S. District Court that will increase the number of plasma donors in the months ahead.
The company had its best quarter in plasma, and guides for it to continue to grow at a good pace.
Since its 52-week low in mid-May 2022, the company has more than doubled its share price, pointing to much of the company's near-term future performance already being priced in.
In this article we'll look at some of the progress it has made in its performance, its heavy reliance on plasma to drive the business, and how that is likely to play out going forward.
We'll also look at its ancillary business to see what part they're playing in the company's outlook.
Recent performance
Because I want to do a deep dive on the plasma business of PAYS, I'm going to primarily focus on the numbers in this section of the article, with not much commentary on the impetus behind them. In the next section I'll tie that together.
The main thing to take into consideration is plasma accounts for approximately 90 percent of revenue for PAYS, so when looking at the numbers, they essentially reflect the plasma business, with a little side contribution of 10 percent from Pharma and Other.
With that in mind, revenue in the third quarter was $10.6 million, up $2.8 million, or 36 percent year-over-year. Revenue from plasma accounted for $9.8 million of the total.
Revenue from Pharma was $693,000, an increase of 5 percent over last year in the same reporting period, and revenue from Other was $73,000, a gain of 3 percent over the third quarter of 2021.
Net income in the quarter was $852,000, or $0.02 per share, an improvement over the net loss of $271,000 or $0.01 per share in Q3 last year.
At the end of the third quarter PAYS had $8 million in cash and no debt.
For full-year 2022, the company guided for revenue to reach $38.15 million to $38.25 million, with plasma accounting for over 90 percent of total revenue.
Gross margins for all of 2022 are projected to be from $21 million to $21.25 million.
With the company trading at a 52-week low of $1.15 per share on May 12, 2022, the company has since jumped to a 52-week high of $3.25 per share, before pulling back to $2.72 per share as I write.
Based upon its recent performance and guidance, I think that's close to an accurate valuation of the stock, although with plasma demand not going away and an increase in potential donors, there is more room for upside in the near and long term, as people look for ways to sustainably supplement their income in difficult economic conditions.
On the Price/Sales side of its numbers on a FWD basis, PAYS stands at 3.72 - not a great number but not terrible either. But on the other hand, as measured by the sector medium, it's behind the FWD P/S of the industry average of 2.50.
If momentum in its plasma business continues, P/S numbers are probably going to get better.
Its plasma business
Since about 90 percent of the revenue of PAYS comes from its plasma business, understanding where that stands in relationship to the company is vital to knowing how it's going to perform in the future.
As far as the plasma industry itself, demand is never going away, and will indefinitely increase into the future. It's never going to be a question of demand, it's more of a question of supply in the market sector.
To that end, a recent preliminary injunction on September 16, 2022, from the U.S. District Court allows "Mexican nationals with a valid B1, B2 visa to resume donating plasma in the U.S." After the decision, those plasma collection centers that were affected started to accelerate donations immediately after the injunction.
Consequently, this will be a tailwind for PAYS, which should be able to leverage the increased plasma supply as it continues to grow its plasma center customer base.
In the third quarter PAYS added another 13 plasma centers, ending the reporting period with 450 centers that use its services. The company grew revenue organically and via new wins. With one of its plasma customers closing and consolidating 13 of its centers, the number of centers at the end of 2022 are expected to be slightly down to 445.
In the quarter being reported the average revenue generated per plasma center on a monthly basis was $7,384, against the monthly average of $6,542 last year in the same quarter. Concerning the risk in its plasma business, if there is any reverse in direction of its wins and customer base, the share price is going to take a big hit. For that reason, it would be beneficial if the company was able to grow other business lines that would offset some of that risk in the months and years ahead.
I don't see any short-term issues, but with over 90 percent of its revenue being in one segment of the market, it's something investors need to watch, even as it expands its plasma footprint.
Pharma
In regard to diversifying its revenue streams, its other businesses are pharma and patient affordability. As noted above, Pharma generated $693,000 in revenue in the third quarter of 2022.
Looking ahead to 2023, there will no longer be any revenue from its higher-margin pre-paid business, so that will have an impact on revenue and earnings in Pharma over the next year.
In its patient affordability business, the company added another couple of program launches in the vertical, including retail and specialty pharmaceutical products.
PAYS is working on building long-term partnerships in the segment that would result in ongoing growth if they bear fruit. There is growing interest in the business, but it's going to take time to grow and have an impact on the top and bottom lines of PAYS. Management said the pipeline in patient affordability in Q4 "looks robust," and if it lands the business, it will provide some clarity as to how it will perform as a percentage of overall revenue. Obviously, it'll take more than a quarter or two to determine outcomes, but it should provide some visibility on its potential.
Conclusion
I don't see anything with PAYS changing over the next couple of years in relationship to plasma revenue remaining the vast majority of its business. And even while it's working on developing other revenue streams, it's expected to continue grow its share of the plasma market.
Under that scenario, it would boost revenue in that key business, and even if there is decent progress in its secondary businesses, it could represent an ever greater percentage of revenue because the probability growth in plasma will outpace the growth in pharma and patient affordability. That could change over time, but I don't see it happening in the near future.
Even with its heavy reliance on its plasma business to drive growth, along with the accompanying risk that presents to the company, I don't think there will be any disruption anytime soon.
Under the current economic conditions where people are looking for consistent ways to boost income, and the permanent and growing demand associated with the plasma industry, there is little to suggest PAYS is going to experience a disruption in its momentum and growth, other than a competitor grabbing a significant piece of its business.
But based upon its performance, that doesn't appear to be a major threat, but it could happen in the future, especially if the plasma sector grows faster than it historically has based upon the current economic conditions. Under that scenario a larger player could compete for a piece of the pie if it gets big enough to have an impact on the performance of the company.
Outside of that, PAYS should continue to grow at a measured pace, and if it continues to win in 2023, it would
then why are you bullish?
looking mighty spiffy----pays + tutes = pps growth.
i was replying to pual---------your concerns and sharing is welcome
fair question- why would you announce on a message board that you are going to "reduce your position seriously" BEFORE you do it? tia
i was a single dad raising my daughter as a baby--------PATIENCE! I so learned. Haircuts happen. lol This is one mighty fine product. The tail will catch up to the snout pps-wise eventually. Though janey has a point with her "mixed bag" impression, i see things far more brightly.----------Fixing manufacturing issue can't be THAT hard to assure supply for great demand. Mgmt needs to fix that and then pr it. 1.00+++ pps should result promptly.---Normally, i just don't fancy much anything china because of their arrogant geopolitical attitude as of late. But man oh man! What a PERFECT market for an israeli company to get a shot at. The chinese people TRUST israeli products. We will see.---------------And for PUAL, i'm betting on WORD OF MOUTH advertising. Babyf is in SO MANY different venues, that ELSE name will be well known very soon.----------
Else Nutrition Reports 3Q2022 Financial Results
Else Nutrition Holdings Inc.
Mon, November 14, 2022 at 6:00 AM·8 min read
In this article:
BABYF
+26.04%
Logo
Logo
Conference call will be held on November 14th at 10AM ET
VANCOUVER, British Columbia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC (BABY) (BABYF) (0YL.F) ("Else" or the "Company") the Plant-Based baby, toddler and children nutrition company, today reported third quarter 2022 financial results for the period ending September 30, 2022. The financial statements and MD&A are available on SEDAR under the Company’s profile.
Third Quarter 2022 Financial Highlights
Revenues were $2.2M, an 83% increase versus 1.2M in 3Q21, and 4% decline versus $2.31M in 2Q22. The growth pause in revenues was due to a temporary product shortage driven by a mechanical malfunction at the Company’s US facility, which delayed production by about six weeks. The demand for the products stayed very high. Management estimates the revenue loss from the malfunction was roughly $0.3M-$0.5M in 3Q22.
Sales in 3Q22 on Amazon.com increased 7% versus 2Q22. Demand exceeded supply during the quarter as the Company made the decision to pull back on supplying Amazon.com and its own e-store, to be able to fulfill all orders from brick-and-mortar retailers.
Else products are listed in over 4,500 stores in North America, selling in over 3,400 stores already, compared with 1,200 stores in 1Q22. New 3Q22 retail chains include Walmart (400+ doors), CVS (1,000+ doors), Win Dixie (500+ doors), BuyBuyBaby (133 doors), Giant Food (161 doors), London Drugs (79 doors in BC and Alberta), Metro Ontario stores (139 stores in Ontario), and more. Management expects to surpass 5,000 listed stores and 10,000 Points of distribution by the end of 2022.
Cash balance as of September 31, 2022, was $17.4M CAD (including restricted cash and short-term bank deposit).
The Company had no loans liability as of September 30, 2022.
Recent Business Highlights
Expanded US retail presence to more than 4,500 stores in the United Stated and Canada, including the recent launches in CVS, London Drugs, Winne-Dixie, and Metro Ontario stores. continuing to increase retail sales velocity and product range in existing stores, and adding key mass and grocery chains to our customer list
Entered the Canadian market with the launch on Amazon.ca, and in brick-and-mortar stores, experiencing an unexpectedly fast market acceptance, interest, and demand. Expecting to be listed in more than 1,100 Canadian stores by the end of 2022.
Entered the Chinese market with the launch of its flagship Chinese store on Tmall Global. The company will be selling its Toddler Formula, Kids nutritional drinks and Baby Cereal products directly to Chinese consumers through the store.
The Company plans to enter Western Europe in 1H2023. The initial launch will be in the UK via Amazon, with other countries to follow.
Else Nutrition Kids Shakes are sold in 400 Walmart stores in 35 states including California, Florida, and Texas, with other products to follow soon.
Else Super Cereal, the first US cereal brand certified safe from heavy metals, reached the best-seller status in its category on Amazon.com, within months of its launch.
Successfully completed the second and last preclinical study on its infant formula, setting the path to FDA approval.
In final preparations for the commencement of the FDA clinical study, awaiting control formula availability.
Management Commentary
Hamutal Yitzhak, CEO of Else Nutrition, commented, “We are pleased to see the demand for our products continue to grow in 3Q22 and the very successful launch in Canada. We are also very excited to see first sales in China (Cross-Border online) as this is by far the largest market in the world with the highest growth potential for Else.
In the third quarter we incurred unforeseen manufacturing challenges which resulted in product shortages that prohibited us from adequately supplying the strong and growing demand for our products. The shortfall of products was further caused by the strong demand in May and June, which depleted our inventory levels heading into 3Q. We are working closely with our manufacturing partner to increase production and resolve the inventory shortage issues as soon as possible. From a long-term standpoint, we are working diligently on securing additional manufacturing facilities in North America and Europe by the beginning of 2023, in order to better diversify our production capacity.”
We are very enthusiastic about our international expansion. Our entry into Canada in August is off to a spectacular start, as initial demand is multiple times our initial expectations. Our marketing efforts over the past years in the US have created pent-up demand for our unique products in Canada, and we are excited to see this market grow rapidly. In June, we announced our entry into the Chinese market via an agreement with Baozun, a leading E-commerce distributor in China, and in September we launched our flagship Chinese store on Tmall Global. Furthermore, we expect to enter the UK and Australia in the first half of 2023.
Our brick-and-mortar expansion is exceeding our expectations. We are currently listed in over 4,500 retail doors in the US and Canada, exceeding our stated goal of listing 4,000 doors by the end of 2022. Given the extraordinary enthusiasm from retailers for our products, we now expect to reach about 5,000 stores by the end of 2022. Importantly, we are now selling on some of the most well-known online platforms and distributors such as Walmart.com, Kroger.com, UNFI, and KeHE.”
FDA Update
In Q4 2021 Else concluded a successful preclinical safety study of its plant-based infant formula, as part of the pathway to bring its Infant formulation to market.
The study results demonstrated proper growth, similar to dairy-based infant formula, in a neonatal preclinical model, which is a key first step on the path with the US Food and Drug Administration (FDA), as well as with other regulatory authorities, to demonstrate safety and nutrient bioavailability of the infant formula and its ingredients. In Q2, the results of the study were accepted for presentation in two key international pediatric nutrition scientific conferences and have been published in a scientific medical peer-reviewed journal. Else is in close communication with the FDA, sharing its plans and results to receive their guidance throughout the process of Else’s infant formula development.
In Q2 2022 Else conducted a second preclinical study, demonstrating the quality of the infant formula protein as part of the FDA requirements for new infant formula to be marketed in the US. Else is working on final preparations for the infant growth clinical study for the FDA and European permits planned to start by early 2023 and conclude in early 2024.
Clinical Research Demonstrating Product Claims
Else started the first clinical study to demonstrate the tolerance claim of its products in a specific intolerant children population.
A second clinical study to be conducted on a healthy toddler population to demonstrate healthy growth has been approved by the ethical committee and should begin very soon.
In 2023 the Company plans to continue research activity demonstrating the safety and tolerability of the infant formula as well as to provide scientific support for Else products including preparation for additional clinical studies.
Conference Call
Hamutal Yitzhak, CEO and Co-Founder, will hold a conference call to discuss the quarter's financial results at 10:00 a.m. (Eastern Time) on November 14, 2022.
Interested parties can listen via a live webcast, from the link available in the Investors section of the Company's website or at https://app.webinar.net/AMgJ03EoQNW.
A replay will be available after the call, in the Investors section of the Company's website at https://app.webinar.net/AMgJ03EoQNW.
About Else Nutrition Holdings Inc.
Else Nutrition Holdings Inc. is a food and nutrition company in the international expansion stage focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the "2017 Best Health and Diet Solutions" award at Milan's Global Food Innovation Summit. The holding company, Else Nutrition Holdings Inc., is a publicly-traded company, listed on TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets Q.X. board under the trading symbol BABYF and the Frankfurt Exchange under the symbol 0YL. Since launching its Plant-Based Complete Nutrition for Toddlers, made of whole foods, almonds, buckwheat, and tapioca, the brand has received thousands of powerful testimonials and reviews from parents and gained national retailer support from Sprouts Farmers Market, and achieved rapid sales growth. Else became the #1 Best Seller on Amazon in the Fall of 2020 in the New Baby & Toddler Formula Category. It recently won the 'Best Dairy Alternative' Award 2021 at World Plant-Based Expo and was a Nexty Award Finalist at Expo West 2022 in the Plant-Based lifestyle category.
Investor Relations Contact:
RBMG – RB Milestone Group LLC
Trevor Brucato, Managing Director
E: Baby@rbmilestone.com
www.rbmilestone.com
Lytham Partners, LLC
Mr. Ben Shamsian
New York | Phoenix
E: shamsian@lythampartners.com
P: 646-829-9701
Toronto Stock Exchange
Neither the Toronto Stock Exchange nor its regulation services provider (as that term is defined in the policies of the Toronto Stock Exchange) a responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
they'll be coming back....too much logic in this play now. Perhaps after we grace 3.00 once more--------and then 5.00. Next earnings should be the golden goose now that we're back so stolidly from this recent qtr.--------I'm in adding mode once more- at my leisure.
me, too! But i'm still sticking to my guns here in pays. Funny, but as most all of my under-the-radar plays have failed, pays seems by far the brightest...despite its reluctance to break out. It's been one bad biden year for me in stocks. I did get two doubles in oil plays that broke me even- but nothing else held its mud for me. As ebrie properly suggests, pays is a recession play. If only more could come to get to know that soon!
i think so, too---this is the big "B"'s market.....and i don't think pays can be politicized. (THANK GOD!)---- Kudos to mgmt for results, too. Next qtr should be absolutely beeeeutiful. We be back.
can we get some upgrades, please? An insider buy might be nice. Tick-tock. Perfect stock for these biden times.
now we are definitively one grand hold and add stock once more- glta
US news
‘I’m selling my blood’: millions in US can’t make ends meet with two jobs
More Americans have been working two or more jobs over the past few decades, census data shows
People speak with recruiters at a job fair in Los Angeles.
People speak with recruiters at a job fair in Los Angeles. Photograph: Étienne Laurent/EPA
Michael Sainato
Sat 5 Nov 2022 05.00 EDT
Millions of Americans are currently working two or more jobs in order to make ends meet, as global inflation and corporations jacking up prices have sent prices of food, gas, housing, health insurance and other necessities soaring in the past year.
Cashe Lewis, 31, of Denver, Colorado works two jobs and is currently trying to find a third job to cover the recent $200 monthly rent increase to her apartment. She works days as a barista at Starbucks, but claims it’s been difficult to get enough hours even with taking extra shifts whenever she can due to scheduling cuts as part of the crackdown on union organizing by management.
At night she works at a convenience store because the hours are reliable, and works six days a week, often 16 hours a day.
“I’m exhausted all the time,” said Lewis. “On the one day I have off a week, I donate plasma for extra money. I’m literally selling my blood to eat because I have no choice.”
Her partner suffers from epilepsy and can’t work full-time hours because of it. Even with insurance, their medication is expensive and she spends about half of a two-week paycheck at Starbucks to cover the health insurance premiums.
Over the past five years, she has struggled with homelessness, and was previously fired from her job for sleeping in her car behind her place of employment.
“All of my friends and family work multiple jobs as well, just trying to keep our heads above water. Nothing is affordable and the roadblocks set up to keep people in the cycle of poverty benefit the most wealthy members of our society,” added Lewis. “We aren’t living, we’re barely surviving and we have no choice but to keep doing it.”
More Americans have been working two or more jobs over the past few decades, according to data from the US census, with women more likely than men to have multiple jobs and multiple jobholders most prevalent among low-wage workers.
Laura Richwine of Omaha, Nebraska, works two jobs, one in fraud prevention and the other doing administrative work, and had previously been working three jobs to keep up with hefty medical bills she’s been facing since being hit by a car in 2014.
“It’s rough and I barely have any energy to keep up with much else,” said Richwine. “I’ve got a bachelor’s degree and have been working for over 10 years, but up until this year I had never had a job that paid more than $15 an hour. Many places around me still only offer Nebraska minimum wage, which is $9 an hour. You can hardly even buy food with that amount.”
Based on data from the Bureau of Labor Statistics, more than 400,000 Americans work two full-time jobs. In September 2022, 4.9% of all the more than 164 million US workers held two or more job positions, over 7.7 million workers.
Though US census data estimates these rates and numbers to be much higher, at 7.8% in the most recent year where data is available, 2018, about 13 million workers, while BLS data at the time estimated 5.0% of the workforce holding multiple jobs.
Both data sets are considered an underestimate of the number of multiple jobholders in the US labor market due to constrictions on what is defined as a multiple jobholder and the lack of data on self-employment, such as gig workers.
An annual survey sponsored by the Federal Reserve Board estimated an even higher number of workers in multiple jobs, at 16.4% in 2019, about 26.5 million workers.
Many of these workers holding multiple jobs are doing so to try to make ends meet and often working longer than 40 hours a week.
Robert Weaver of Lawrence, Kansas, currently works two jobs as a theater technician and delivery driver, 30 to 35 hours a week at his primary job and about 20 at his second job.
He explained that he works two jobs because he cannot find a single, full-time position in his area that matches with his college degree. Most of his disposable income goes toward paying off credit cards, taxes, surprise bills like car repairs, and medical expenses.
“There isn’t enough money to be able to afford a home or even rent from just one job on your own,” said Weaver. “Everyone is in debt and it’s looking like we will never pay it off, ever.”
Liora Engel, 37, of Vermont, took on two additional jobs, working at a deli and another at a convenience store, earlier this year on top of her full-time job in media, to try to boost her income and cover expenses while going through a divorce.
After working 70-hour weeks, she left her full-time job due to burnout, but still works two jobs while trying to get a side hustle off the ground and limiting her work hours to no more than 50 hours a week.
“It’s kind of like, how much of your soul are you willing to sell in order to be financially independent or to make sure that you can pay your bills?” said Engel.
this arena spends freely- richest in the usa (my sister lives in fallsmeade, md)---price of our product won't matter here- only quality and reputation. More million dollar homes here than imaginable. WORD OF MOUTH IS HOW THE RICH HERE "KNOW".-----This should shoot up sales- not much marketing needed.--i dedicate this news to pual accordingly-
Else Toddler and Kids products are now available in the Ahold Delhaize-owned Giant Food supermarket and pharmacy chain. The distribution more than doubles Else Nutrition store count in Delaware, Maryland, Virginia, and the District of Columbia
Giant Foods
Giant Foods
Giant Foods
Giant
Giant
VANCOUVER, British Columbia, Nov. 03, 2022 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC. (BABY) (BABYF) (0YL.F) ("Else" or the "Company"), announces that Giant Food has placed Else Nutrition Toddler Complete Nutrition and Kids Vanilla Shake products in 161 locations. This is a significant increase in Else product availability in the Eastern States of Delaware, Maryland, Virginia, and the District of Columbia with more than double the number of retail locations now available.
This is also the first Ahold Delhaize account for Else Nutrition and a major milestone for the company working with another large, multi-national retailer.
Highlights:
Else Nutrition signs first account with Ahold Delhaize, another large, multi-national retailer
Giant Food has placed Else Nutrition Toddler Complete Nutrition and Kids Vanilla Shake products in 161 locations.
More than doubles the current store count for the Eastern States; Delaware, Maryland, Virginia, and the District of Columbia.
“We are proud to work with Giant which has a rich history of providing quality to consumers since 1936,” said Hamutal Yitzhak, CEO, and Co-Founder of Else Nutrition. “Giant is a retailer focused on the healthiest eating choices, so we see a strategic match here with Else, by providing our complete nutrition, minimally processed products to Giant consumers and families.”
With the combination of Giant grocery and pharmacy locations and the doubling of the Eastern State store count stocking Else products, the company expects a significant increase in demand for Toddler and Kids products in the region.
“Throughout the year we have seen an increase in demand from all regions for the Else products. A material increase in coverage in these states with Giant will expose many new families to the clean-label choice that Else provides, and we expect to see the demand increase even more in these areas,” added Hamutal Yitzhak, CEO, and Co-Founder of Else Nutrition.
i'll watch it- but in this kid of overall mkt, they will need major news to gain interest enough for pps to grow----u know i'm watching all our mentions around here, however. glty
woohoo! heck of a tune- primitive but to the point-
dedicated to mgmt
got it covered
that's been my expectation---tick tock
I dedicate this to our sleeping baby:
i won't scalp (macabre) tiny shares from babyf until .70 with feeling-------------and my scalping will only be 1%! lol---willrun that into pays.
long/strong in that regard---see how i spanked the babyf. She might mind now....
i spanked the babyf- now she will behave......
i've been wondering that since biden election-----i managed to eek out one double since in vet- but i watch or own 50 stocks and biden's stk mkt sucks. One of my worst years, i reckon. Nothing keeps gains. Insidious death by drips or paint drying.
thks nerdguy
baby acting brat-like----break us out someone---i think we be in bull up until election...and the iran-israel war risk is now dying in their iranian multi-city protesting streets-------i'm wanting to add here.....thoughts about adding, fellow baby burper's?
with your daily rigor pointing that all out on this board, don't you think she has already been made aware of your opinion? Incessantly beating the drum so?----------Now, it's just you flailing away all for naught. We are stuck with the status quo until we're not in pps. Why not take a new tack? (with all due respect)
our baby is suffering pps child abuse-----i'm holding until authorities correct our situation............
some of the finest weather of the year here---------i feel for the other part of fla, for sure----------mother nature can be a biotch. I have some 40+ years of hurricane exposures. They are more property damage than anything else if you have any sense preparing. MSM hypes them because they tie them to the global warming agenda. For instance, "dozens died from ian gaining coverage 24/7...yet 80000 have died from fentanyl that get rare air play in comparison.
is she a momma herself- this ceo?--i was a momma myself years ago raising my wee daughter by myself as her sole parent---having NEVER been around a baby before..........so it really does change all perspective. As a guy i FREAKED OUT....the slightest fever, the burps, the teething-----------i had no lessons----no school training----but she's a lawyer today. I guess i got through it. But i might have preferred an else product in this day and age. I think normal bottles blew my babies stomach up...so that's my question to the ceo- is she a momma?
good news-Paysign, Inc. Applauds Preliminary Injunction of Plasma Ban
HENDERSON, Nev. – September 27, 2022 – (Business Wire) – Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced that on September 16, 2022, the United States District Court issued a preliminary injunction preventing the United States Customs and Border Protection (CBP) from continuing to enforce its ban on plasma donations by Mexican nationals.
“Paysign applauds this decision as it allows our plasma clients to resume accepting plasma donations from Mexican nationals who enter the U.S. on a valid B-1/B-2 visa,” said Mark Newcomer, Paysign CEO. “Paysign would like to welcome back these donors and we appreciate their contribution to the supply of source plasma, which is used in therapies to treat a variety of rare diseases worldwide.”
chill pill time, folks: babies don't grow up overnight...